DBC1 is a crucial endogenic inhibitor of SIRT1, which has been implicated in cancer progression and deacetylates p53, leading to a downregulation of its transcriptional activity and thereby to an enhancement of cell proliferation [105]. Here, TP53 is linked to cancer.